CXCL12 and diabetic kidney disease: Another study showed that linagliptin attenuated the progression of albuminuria, glomerulosclerosis, periglomerular fibrosis, podocyte loss, and renal oxidative stress in GLP-1R-deficient diabetic mice, suggesting that linagliptin inhibits DKD in a SDF-1-dependent manner [82].